The regular meetings of Beacon Angels in 2024 covered the following:
January 9, 2024
Predictive Healthcare & Verisense Health
Beacon Angels members conducted the following new business at its meeting on Tuesday, January 9, 2024:
We entertained new funding proposals from the following:
- Predictive Healthcare, of Bedford, MA develops and markets a predictive postoperative patient wound healing outcome digital platform called MyHealthPal.
- Verisense Health, which provides digital health management services via proprietary wearable sensors.
We heard a follow-on funding presentation:
- Realplay, offering AI-driven sports video solutions for youth baseball and softball complexes. Selling B2B systems with a B2C subscription platform for players, parents, fans, coaches and scouts.
We considered multiple funding rounds, by Series number:
Completed
- 124 Jaia Robotics.
- 125 Imago Rehab.
Pending
- 112B Theromics, developing tumor-targeting therapies;
- 122 GelMEDIX, developing gel-form eye therapies; and
- 123 Xeno, developing a weight-loss pill; and
- 126 Mybiometry, offering early warning of asthma attacks up to 20 days in advance using intelligent diagnostics and connected monitoring.
Members reported on companies in due diligence:
- RealNose, offers AI-trained, bio-programmable olfactory sensors that map scent profiles, initially to help doctors detect prostate cancer in patients.
- RestauRent, a B2B SAAS platform to directly book private events at venues that have event space for 15-300+ guests.
February 13, 2024
Ankored & Robotics88
Beacon Angels members conducted the following new business at its meeting on Tuesday, February 13, 2024:
We entertained new funding proposals from the following:
- Ankored (Seth Lieberman, providing an automated tracking platform designed for small to mid-sized organizations to streamline their compliance, including document collection, clearances, training, certificates, approvals, and audit logs.
- Robotics88, delivering aerial drones along with a mapping service subscription to land managers who conduct prescribed burns. The drones provide pre-burn fire prediction in the planning stage and post-burn objective evaluation.
We heard updates from the Beacon portfolio company,
- NF2 Therapeutics, developing gene replacement therapy to prevent deafness, loss of mobility and devastating NF2 brain tumors and a targeted antibody-drug conjugate to treat NF2 meningiomas.
Swiggart reported on funding rounds, by Series number, as follows.
Completed
- 123 Xeno (Series A ext’n $1.0 MM new money, $1.5 MM debt conversion) (PR=$85K; $177K invested);
Pending
- 112B Theromics developing tumor-targeting therapies (30K invested);
- 122 GelMEDIX (PR=$223K; $190K collected);
- 126 Mybiometry (Smith) offering early warning of asthma attacks up to 20 days in advance using intelligent diagnostics and connected monitoring ($35K collected).
Members reported on companies in due diligence:
- RealNose (Jim Doscher)) offers AI-trained, bio-programmable olfactory sensors that map scent profiles, initially to help doctors detect prostate cancer in patients.
- RestauRent (DD by Smith, Doscher & Jack Wagner), a B2B SAAS platform to directly book private events at venues that have event space for 15-300+ guests.
March 12, 2024
Glycologix, Agile Devices & AI Lean
At the Beacon Angels meeting on Tuesday, March 12, 2024, we entertained new funding presentations as follows:
- Glycologix, developing, GLX-100, a biopolymer medical device for the novel treatment of the underserved millions with interstitial cystitis/bladder pain syndrome.
- Agile Devices, whichhas developed the FDA-cleared Angler® Steerable and Deflectable Microcatheter, a novel device with a fully intraoperative active tip control for neurovascular, coronary and peripheral use cases; and
- AI Lean, which outsources the lien-to-auction process for self-storage owners, automating collections, liens and auctions management.
Members reported on pending funding rounds, by Series number.
- 112B Theromics, developing tumor-targeting therapies ($30K held);
- 116B Realplay, providing video highlights for youth sports ($40K invested)
- 122 GelMEDIX improving drug delivery for the eye ($190k invested, of which $76K held in escrow); and
- 126 myBiometry developing an advanced early-warning system for asthma attacks ($35K held awaiting company docs).
Members reported on companies in due diligence:
- Surgicure Technologies, developing a device to improve intubation quality and safety.
Members reported on pending funding rounds, by Series number.
- 112B Theromics, developing tumor-targeting therapies;
- 116B Realplay, providing video highlights for youth sports;
- 122 GelMEDIX improving drug delivery for the eye; and
- 126 myBiometry developing an advanced early-warning system for asthma attacks ($35K held awaiting company docs).
April 9, 2024
AGED Diagnostics, Vuja De Sciences & PneumoNIX Medical
At the Beacon Angels meeting on April 9, 2024, we entertained new funding presentations as follows:
- AGED Diagnostics (Rachel Zayas – a pre-clinical diagnostics venture developing blood tests for fatty liver disease and liver fibrosis.
- Vuja De Sciences – providing a novel approach to prevent cancer recurrence and progression.
- PneumoNIX Medical – offering a product to eliminate complications of tissue biopsy by sealing the biopsy track at the outset.
Members reported on companies in due diligence:
- Surgicure Technologies,
- Glycologix,
- Agile Devices &
- AI Lean.
May 14, 2024
Relavo & EMBioSys
At the Beacon Angels meeting on May 14, 2024, we conducted the following business.
We entertained funding presentations from the following:
- Relavo, developing a self-disinfecting connection device for kidney failure patients to receive peritoneal dialysis (PD) safely and at home; and
- EMBioSys, developing therapeutic wearable garments to treat solid metastatic cancers with low level induced electric fields (iEFs).
We also heard Beacon portfolio updates and follow-up presentations as follows:
- QSM Diagnostic (Edgar Goluch), selling diagnostic mail-in kits for veterinarians rapidly and accurately to diagnose bacterial infections in pets; and
- Zeptive, selling patented battery-powered and wireless vape/smoke & safety sensors for schools to detect risky behavior without cameras.
Members reported on pending and closed funding rounds, by Series number:
- 126 myBiometry developing an advanced early-warning system for asthma attacks.
- 112B Theromics, developing tumor-targeting therapies;
- 116B Realplay, providing video highlights for youth sports; and
- 122 GelMEDIX improving drug delivery for the eye.
Members reported on companies in due diligence:
- AI Lean; and
- AGED Diagnostics.
June 14, 2024
WAHTS Hearing, DeepLook Medical & RelayVoice
At the Beacon Angels meeting on June 14, 2024, we undertook the following activities:
We entertained new funding presentations as follows:
- WAHTS Hearing, offering a proprietary wireless headset to enable a person’s hearing to be tested from any location;
- DeepLook Medical, offering FDA-approved shape-recognition software for better screening, diagnosis and treatment of breast cancer via dense mammography; and
- RelayVoice, personalizing volume phone calls to enable highly personalized voicemail drops at scale.
Members reported on pending and closed funding rounds, by Series number:
- 126 myBiometry developing an advanced early-warning system for asthma attacks; and
- 128 AI Lean, offering a software system for the self-storage operator to manage its liens and conduct its auctions.
Members reported on companies in due diligence:
- AI Lean; and
- AGED Diagnostics.
July 9, 2024
SplitBrick, ClearCut Surgical & Surgicure
Beacon Angels undertook the following at its meeting on July 9, 2024:
We entertained new funding presentations as follows:
- SplitBrick, offering a platform for fractional real estate investing with low-commission trading of any property for sale nationwide.
- ClearCut Surgical, developing electrocautery surgeon’s tools that incorporate smoke evacuation, fluid suction, and blunt dissection.
- Surgicure, a medical device company innovating airway management for civilian and military use.
Members reported on pending funding rounds, by Series number.
- 116C Realplay bridge note;
- 128 AI Lean, developing software to automate the lien-to-auction process for self-storage owners;
- 129 Neosoma, developing a SAAS clinical management platform for neuro-oncology; and
- 130 QSM Diagnostics, delivering rapid diagnostic tests.
September 10, 2024
FreezeNit, AiM Medical Robotics
At its meeting on September 10, 2024, Beacon Angels conducted the following business:
We entertained new funding presentations as follows:
- FreezeNit, a patent-pending technology that kills head lice and nits using only cold CO2 gas without the need for harmful pesticides, or messy prescriptions; and
- AiM Medical Robotics, a neurosurgical robotics company commercializing a unique compact MRI-compatible surgical robot for brain surgery.
Beacon portfolio update:
- Pykus Therapeutics, developing a better means to secure the retina following reattachment surgery.
Report on companies in due diligence:
- ClearCut Surgical, developing electrocautery surgeons’ tools that incorporate smoke evacuation, fluid suction, and blunt dissection.
- WAHTS Hearing.
Report on pending funding rounds by Series number.
- 129 QSM Diagnostics, delivering rapid diagnostic test kits and devices to pet owners and veterinarians.
- 130 Surgicure, a medical device company that is innovating airway management for civilian and military use; and
- 131 Pykus.
October 8, 2024
TerraFlow & CellField Technologies
Beacon conducted the following business at its October 8, 2024 meeting:
We entertained funding proposals from the following:
- TerraFlow, selling to pharma companies a blood-to-biomarker discovery engine that delivers a complete immunophenotyping report in 24 hours; and
- CellField Technologies, developing a patented system for drug development companies to test drug efficacy on human joint tissues without animal testing.
We entertained a portfolio company update from:
- Jaia Robotics, delivering low-cost, micro-sized, high-speed Aquatic Drones for data collection and payload delivery.
Members reported on current funding rounds:
- S129 – QSM Diagnostics,
- S130 – Surgicure &
- S131 – Pykus Therapeutics.
Beacon Angels 